Extended Anti-CGRP Therapy: New Hope for Migraine Relief

Research Summary

A recent narrative review published in the Pain Management journal sheds light on the delayed effects of anti-CGRP therapy for migraine, revealing that some patients may need more than the usual 3-month treatment period to see benefits. While these therapies, which target the calcitonin gene-related peptide, are generally effective in reducing migraine frequency, real-world data shows that about one-third of non-responders at 3 months improve by 6 months. Moreover, some patients experience significant relief only after 6 to 12 months. These findings highlight the importance of extending treatment duration to maximize benefits, suggesting a rethink of conventional therapy timelines for better patient outcomes.

Study Details

📄 Title: Late response to anti-CGRP therapy for migraine.

👥 Research Team: Marsico O, Lioi M, Trimboli M

📚 Published In: Pain Manag

📅 Publication Date: 2025 Aug 21

🔗 Read Study

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.